Adherence 2018 (13th International Conference on HIV Treatment and Prevention Adherence) will take place June 8-10, 2018, at the Loews Miami Beach Hotel in Miami, FL, USA. Sponsored by the International Association of Providers of AIDS Care (IAPAC), this annual series of conferences features the presentation and discussion of HIV treatment and biomedical prevention adherence research, as well as current behavioral and clinical perspectives in practicum, within the context of achieving an optimized continuum of HIV care and prevention. Continue reading “Adherence 2018 announcement”
Visit the website for more information: http://journals.plos.org
CROI 2018 will be held from March 4 to 7, 2018, in Boston, Massachusetts, at the Hynes Convention Center. Please note that CROI 2018 will be held from Sunday to Wednesday.
CROI has simplified and expanded the registration process, especially for abstract submitters (regardless of if the work was accepted). They are increasing the limit on number of authors from 10 to 15, and allowing authors on non-accepted abstracts to register before we open for general registration. They are particularly interested in encouraging new investigators to submit to and attend CROI.
Abstract deadline is Sep 27, per slide.
Important Dates and Details
- September 27: General Abstract Submission Closes
- January 16: Late Breaking Abstract Submission Closes
- New Next year: easier and earlier access to registration for Abstract Submitters and their collaborators
More details at: www.CROIconference.org
*CROI begins on a Sunday next year
The NCI invites to join us at the 16th International Conference on Malignancies in HIV/AIDS (ICMH) previously named the International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI). The meeting will take place October 23-24, 2017, at the Lister Hill Center Auditorium on the campus of the National Institutes of Health in Bethesda, Maryland.
This meeting is presented by the Office of HIV and AIDS Malignancy, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services.
Recent advances in areas such as viral oncology, immunology, genetics, epidemiology, pathogenesis, early diagnosis, and clinical investigation of malignant diseases associated with HIV and other acquired immunodeficiency states will be shared at this conference. Our objective is to facilitate the exchange of information between laboratory and clinical researchers so as to accelerate the translation of basic scientific discoveries into clinical applications.
Registration and further information on
World AIDS Day is 1st December each year, an opportunity for people worldwide to unite in the fight against HIV, show their support for people living with HIV and to commemorate people who have died.
This year, during the same week the WHO launched their 2016 global HIV progress report alongside their updated guidelines on HIV self-testing and partner notification.
Several IeDEA-WHO collaboration analyses from both the 2015 and 2016 rounds of this collaboration were cited in chapter three (Country action and WHO support) of this latest WHO progress report (see pages 28-30 & 38). Many thanks to the IeDEA teams for your continued commitment and support of this evolving and expanding collaboration with WHO.
IeDEA investigators had multiple abstract presentations and other invited talks throughout the pre-conference and main conference programs in July.
We were also invited to join the ALPHA network, the MeSH Consortium, and the HIV Modelling Consortium who hosted a booth in the Exhibition Hall where conference participants could learn more about how these collaborations are utilizing data to guide the global HIV response.
Read the slides “IeDEA at IAS 2016 – Durban, South Africa”
Misdiagnosis of HIV infection has important implications for individuals and for public health. With the exponential expansion of HIV testing using multiple technologies, the potential for both false positive and false negative results has similarly grown.
HIV testing technologies range from rapid diagnostic tests and other technologies that enable testing at the point-of-care or near point-of care, to those that are used exclusively in high-level facilities and laboratories. Although most technologies for HIV testing have high sensitivity and specificity and are highly accurate when used in a validated national algorithm, the volume of tests conducted (over 150 million tests in 2014 alone), could result in thousands of misdiagnosed cases, particularly if not conducted correctly.